The first results of a 6-year follow-up study of a patient with early psoriatic arthritis treated with a treat-to-target strategy
https://doi.org/10.14412/1996-7012-2020-3-91-96
Abstract
The paper characterizes the basic principles of a treat-to-target (T2T) strategy for spondyloarthritis, including psoriatic arthritis (PsA). The data from observational cohort studies suggest that inadequate therapy for PsA increases the risk of structural progression. The results, obtained in the international randomized controlled Tight Control of Psoriatic Arthritis (TICOPA) trial and the Russian open-label observational REMARCA study, have justified the necessity of using the T2T strategy for early-stage PsA. The authors have analyzed their own results of a 6-year follow-up study of a patient with early PsA, in whom the T2T strategy was used.
About the Authors
P. O. Tremaskina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Polina Olegovna Tremaskina
34A, Kashirskoe Shosse, Moscow 115522
E. Yu. Loginova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
T. V. Korotaeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
A. V. Sukhinina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Korotaeva TV. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(6):650-9. (In Russ.). doi: 10.14412/1995-4484-2014-650-659
2. Nasonov EL, Korotaeva TV, Lila AM, Kubanov AA. Can the development of psoriatic arthritis be prevented in patients with psoriasis? Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2019;57(3):250-4. (In Russ.). doi: 10.14412/1995-4484-2019-250-254
3. Scher JU, Ogdie A, Merola JF, et al. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019 Mar; 15(3):153-66. doi: 10.1038/s41584-019-0175-0.
4. Van Mens LJJ, de Jong HM, Fluri I, et al. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a doubleblind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann Rheum Dis. 2019 May;78(5):610-16. doi: 10.1136/annrheumdis-2018-214746. Epub 2019 Feb 26.
5. Guldberg-M ∅ ller J, Cordtz RL, Kristensen LE, et al. Incidence and time trends of joint surgery in patients with psoriatic arthritis: a register-based time series and cohort study from Denmark. Ann Rheum Dis. 2019 Nov; 78(11):1517-23. doi: 10.1136/annrheumdis2019-215313. Epub 2019 Jul 12.
6. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. CJEM. 2017 Mar;19(2): 156-8. doi: 10.1017/cem.2015.105. Epub 2015 Nov 20.
7. Smolen JS, Schöls M, Braun J, et al Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6.
8. Wervers K, Luime JJ, Tchetverikov I, et al. Comparison of disease activity measures in early psoriatic arthritis in usual care. Rheumatology (Oxford). 2019 Dec 1; 58(12):2251-59. doi: 10.1093/rheumatology/kez215.
9. Coates LC, Cook R, Lee KA, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken). 2010 Jul;62(7):970-6. doi: 10.1002/acr.20162.
10. Korotaeva TV, Loginova EYu, Karateev DE, et al. Treat-to-target strategy for early psoriatic arthritis (preliminary results of the REMARCА study). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(4):376–80. (In Russ.). doi: 10.14412/1995-4484-2014-376-380
11. Loginova EYu, Korotaeva TV, Smirnov AV, et al. Specific features of axial skeleton involvement in early psoriatic arthritis (the REMARCA trial). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2016;54(1S):15-9. (In Russ.). doi: 10.14412/1995-4484-2016-1S-15-19
12. Wervers K, Luime JJ, Tchetverikov I, et al. Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis. Arthritis Res Ther. 2019 Jan 16;21(1):25. doi: 10.1186/s13075-0191811-4.
13. Kirkham B, de Vlam K, Li W, et al. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial. Clin Exp Rheumatol. Jan-Feb 2015;33(1):11-9. Epub 2014 Dec 22.
14. Strand V, Mease P, Gossec L, et al. FUTURE 1 study group. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis. 2017 Jan;76(1):203-7. doi: 10.1136/annrheumdis-2015-209055. Epub 2016 May 11.
15. Coates LC, Helliwell PS. Treating to target in psoriatic arthritis: how to implement in clinical practice. Ann Rheum Dis. 2016 Apr;75(4):640-3. doi: 10.1136/annrheumdis2015-208617. Epub 2015 Dec 15.
Review
For citations:
Tremaskina PO, Loginova EY, Korotaeva TV, Sukhinina AV. The first results of a 6-year follow-up study of a patient with early psoriatic arthritis treated with a treat-to-target strategy. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2020;14(3):91-96. https://doi.org/10.14412/1996-7012-2020-3-91-96
Views:
952
Email this article 